Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645204 | PMC |
| http://dx.doi.org/10.4103/aian.aian_523_23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidence, characteristics, and comorbidities of a complete unselected Danish cohort of patients with thymic epithelial tumors.
Acta Oncol
January 2025
Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark.
Background And Purpose: We report the incidence, characteristics, and comorbidities of the complete unselected Danish cohort of patients with thymic epitheliums (TETs), which may serve as evidence for guiding treatment, surveillance, and counselling of TET patients.
Patients And Methods: All patients diagnosed with TETs from January 1st, 2015, to December 31st, 2020, were identified using the Danish Pathology Data Registry. Data on patient characteristics, comorbidities, and tumor histology were collected from electronic medical records available for all patients.
Epidemiology, management and patient needs in myasthenia gravis: an Italian multistakeholder consensus based on Delphi methodology.
BMJ Open
December 2024
Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
Objectives: To provide comprehensive information on the burden of myasthenia gravis (MG) in Italy, including the unmet needs of patients and several other aspects related to the disease, based on skilled viewpoints of MG experts.
Design: Iterative analysis conducted in accordance with the best practices of the Delphi method, including anonymity, controlled feedback, and statistical stability of consensus.
Setting And Participants: 24 clinicians, 18 public health experts and 4 patient associations experts completed all the Delphi iterations between 18 April and 3 July 2023, for a total of 46 participants from several Italian Regions.
Cutoffs on severity metrics for minimal manifestations or better status in patients with generalized myasthenia gravis.
Front Immunol
January 2025
Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan.
International consensus guidance and Japanese clinical guidelines for myasthenia gravis (MG) recommend achieving minimal manifestations or better status (MM-or-better) as the severity component of the treatment goal. However, the subjective nature of determining MM can result in ambiguity regarding this category in clinical practice and clinical trials. This study analyzed severity metrics in a large number of MG patients to propose criteria for MM-or-better.
View Article and Find Full Text PDFPredictive modeling and interpretative analysis of risks of instability in patients with Myasthenia Gravis requiring intensive care unit admission.
Heliyon
December 2024
Department of Neurology, Taipei Medical University - Shuang Ho Hospital, New Taipei City, 235, Taiwan.
Objective: Myasthenia gravis (MG), a low-prevalence autoimmune disorder characterized by clinical heterogeneity and unpredictable disease fluctuations, presents significant risks of acute exacerbations requiring intensive care. These crises contribute substantially to patient morbidity and mortality. This study aimed to develop and validate machine-learning models for predicting intensive care unit (ICU) admission risk among patients with MG-related disease instability.
View Article and Find Full Text PDFPD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024.
Hum Vaccin Immunother
December 2025
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Programmed cell death-1 (PD-1) inhibitors and programmed cell death ligand 1 (PD-L1) inhibitors are considered effective alternatives for the primary treatment of recurrent metastatic cancers. However, they can induce various adverse events affecting multiple organ systems, potentially diminishing patients' quality of life, and even leading to treatment interruptions. Adverse events related to PD-1/PD-L1 inhibitors differ from those associated with CTLA-4 inhibitors and are more commonly observed in the treatment of solid tumors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!